vs

Side-by-side financial comparison of Intapp, Inc. (INTA) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $140.2M, roughly 1.1× Intapp, Inc.). Intapp, Inc. runs the higher net margin — -4.2% vs -5.5%, a 1.3% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 15.7%). Intapp, Inc. produced more free cash flow last quarter ($22.2M vs $13.0M).

Intapp, Inc. is a global provider of cloud-native software solutions designed exclusively for professional services firms, including legal practices, accounting firms, consulting agencies, private equity firms, and investment banks. Its offerings span client lifecycle management, risk and compliance tools, operational workflow automation, and financial performance tracking, with key markets across North America, Europe, and Asia-Pacific.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

INTA vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.1× larger
TARS
$151.7M
$140.2M
INTA
Growing faster (revenue YoY)
TARS
TARS
+112.7% gap
TARS
128.4%
15.7%
INTA
Higher net margin
INTA
INTA
1.3% more per $
INTA
-4.2%
-5.5%
TARS
More free cash flow
INTA
INTA
$9.2M more FCF
INTA
$22.2M
$13.0M
TARS

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
INTA
INTA
TARS
TARS
Revenue
$140.2M
$151.7M
Net Profit
$-5.9M
$-8.4M
Gross Margin
75.0%
Operating Margin
-5.1%
-5.3%
Net Margin
-4.2%
-5.5%
Revenue YoY
15.7%
128.4%
Net Profit YoY
41.9%
63.8%
EPS (diluted)
$-0.07
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
INTA
INTA
TARS
TARS
Q4 25
$140.2M
$151.7M
Q3 25
$139.0M
$118.7M
Q2 25
$102.7M
Q1 25
$78.3M
Q4 24
$66.4M
Q3 24
$48.1M
Q2 24
$40.8M
Q1 24
$27.6M
Net Profit
INTA
INTA
TARS
TARS
Q4 25
$-5.9M
$-8.4M
Q3 25
$-14.4M
$-12.6M
Q2 25
$-20.3M
Q1 25
$-25.1M
Q4 24
$-23.1M
Q3 24
$-23.4M
Q2 24
$-33.3M
Q1 24
$-35.7M
Gross Margin
INTA
INTA
TARS
TARS
Q4 25
75.0%
Q3 25
74.7%
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
INTA
INTA
TARS
TARS
Q4 25
-5.1%
-5.3%
Q3 25
-10.4%
-12.2%
Q2 25
-21.6%
Q1 25
-33.5%
Q4 24
-36.8%
Q3 24
-52.3%
Q2 24
-81.6%
Q1 24
-136.5%
Net Margin
INTA
INTA
TARS
TARS
Q4 25
-4.2%
-5.5%
Q3 25
-10.3%
-10.6%
Q2 25
-19.8%
Q1 25
-32.1%
Q4 24
-34.8%
Q3 24
-48.7%
Q2 24
-81.6%
Q1 24
-129.4%
EPS (diluted)
INTA
INTA
TARS
TARS
Q4 25
$-0.07
$-0.17
Q3 25
$-0.18
$-0.30
Q2 25
$-0.48
Q1 25
$-0.64
Q4 24
$-0.57
Q3 24
$-0.61
Q2 24
$-0.88
Q1 24
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
INTA
INTA
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$191.2M
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$410.2M
$343.4M
Total Assets
$795.2M
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
INTA
INTA
TARS
TARS
Q4 25
$191.2M
$417.3M
Q3 25
$273.4M
$401.8M
Q2 25
$381.1M
Q1 25
$407.9M
Q4 24
$291.4M
Q3 24
$317.0M
Q2 24
$323.6M
Q1 24
$298.5M
Total Debt
INTA
INTA
TARS
TARS
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$29.9M
Stockholders' Equity
INTA
INTA
TARS
TARS
Q4 25
$410.2M
$343.4M
Q3 25
$486.4M
$335.1M
Q2 25
$332.6M
Q1 25
$342.5M
Q4 24
$224.5M
Q3 24
$237.5M
Q2 24
$252.2M
Q1 24
$275.2M
Total Assets
INTA
INTA
TARS
TARS
Q4 25
$795.2M
$562.2M
Q3 25
$823.3M
$534.6M
Q2 25
$495.0M
Q1 25
$500.8M
Q4 24
$377.0M
Q3 24
$376.3M
Q2 24
$376.8M
Q1 24
$349.3M
Debt / Equity
INTA
INTA
TARS
TARS
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
INTA
INTA
TARS
TARS
Operating Cash FlowLast quarter
$22.9M
$19.3M
Free Cash FlowOCF − Capex
$22.2M
$13.0M
FCF MarginFCF / Revenue
15.8%
8.6%
Capex IntensityCapex / Revenue
0.5%
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
INTA
INTA
TARS
TARS
Q4 25
$22.9M
$19.3M
Q3 25
$13.8M
$18.3M
Q2 25
$-29.4M
Q1 25
$-20.7M
Q4 24
$-22.2M
Q3 24
$-8.7M
Q2 24
$-14.4M
Q1 24
$-37.8M
Free Cash Flow
INTA
INTA
TARS
TARS
Q4 25
$22.2M
$13.0M
Q3 25
$13.2M
$16.3M
Q2 25
$-30.4M
Q1 25
$-21.2M
Q4 24
$-22.3M
Q3 24
$-8.9M
Q2 24
$-15.4M
Q1 24
$-38.0M
FCF Margin
INTA
INTA
TARS
TARS
Q4 25
15.8%
8.6%
Q3 25
9.5%
13.8%
Q2 25
-29.6%
Q1 25
-27.1%
Q4 24
-33.5%
Q3 24
-18.6%
Q2 24
-37.8%
Q1 24
-137.5%
Capex Intensity
INTA
INTA
TARS
TARS
Q4 25
0.5%
4.2%
Q3 25
0.4%
1.6%
Q2 25
1.0%
Q1 25
0.8%
Q4 24
0.1%
Q3 24
0.6%
Q2 24
2.5%
Q1 24
0.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

INTA
INTA

Saa S$102.5M73%
License$25.4M18%
Professional Services$12.3M9%

TARS
TARS

Segment breakdown not available.

Related Comparisons